DK1817345T3 - Antistoffer mod tenascin-C - Google Patents
Antistoffer mod tenascin-CInfo
- Publication number
- DK1817345T3 DK1817345T3 DK05813654T DK05813654T DK1817345T3 DK 1817345 T3 DK1817345 T3 DK 1817345T3 DK 05813654 T DK05813654 T DK 05813654T DK 05813654 T DK05813654 T DK 05813654T DK 1817345 T3 DK1817345 T3 DK 1817345T3
- Authority
- DK
- Denmark
- Prior art keywords
- tenascin
- domain
- specific binding
- binding members
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62617304P | 2004-11-09 | 2004-11-09 | |
| US67737605P | 2005-05-03 | 2005-05-03 | |
| PCT/EP2005/011624 WO2006050834A2 (en) | 2004-11-09 | 2005-10-31 | Antibodies against tenascin-c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1817345T3 true DK1817345T3 (da) | 2009-09-28 |
Family
ID=36336853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05813654T DK1817345T3 (da) | 2004-11-09 | 2005-10-31 | Antistoffer mod tenascin-C |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7968685B2 (ja) |
| EP (2) | EP1817345B9 (ja) |
| JP (2) | JP2008518609A (ja) |
| KR (1) | KR20070085892A (ja) |
| CN (1) | CN101090913B (ja) |
| AT (1) | ATE432293T1 (ja) |
| AU (1) | AU2005304031B2 (ja) |
| BR (1) | BRPI0517967B8 (ja) |
| CA (1) | CA2586661A1 (ja) |
| CY (1) | CY1110481T1 (ja) |
| DE (1) | DE602005014665D1 (ja) |
| DK (1) | DK1817345T3 (ja) |
| EA (1) | EA013537B1 (ja) |
| ES (1) | ES2327349T3 (ja) |
| HK (1) | HK1115756A1 (ja) |
| MX (1) | MX2007005582A (ja) |
| PL (1) | PL1817345T3 (ja) |
| PT (1) | PT1817345E (ja) |
| SI (1) | SI1817345T1 (ja) |
| WO (1) | WO2006050834A2 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
| EP2465870A1 (en) * | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| MX2009010639A (es) | 2007-04-02 | 2009-10-23 | Philogen Spa | Nuevo antigeno asociado con la neovasculatura de metastasis tumoral. |
| MX2009013752A (es) * | 2007-06-28 | 2010-02-01 | Philogen Spa | Inmunocitocinas para el tratamiento del cancer en combinacion con agentes quimioterapeuticos. |
| US10202442B2 (en) | 2007-07-25 | 2019-02-12 | Philogen S.P.A. | Antigen associated with lung cancers and lymphomas |
| CN101918443B (zh) | 2007-10-30 | 2013-07-17 | 菲洛根股份公司 | 一种与类风湿性关节炎相关的抗原 |
| WO2009089998A1 (en) * | 2008-01-15 | 2009-07-23 | Philochem Ag | Binding members for tenascin-c domain a2 |
| CA2747154C (en) | 2008-12-19 | 2015-11-10 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| EP2379116B1 (en) | 2009-01-07 | 2015-08-26 | Philogen S.p.A. | Antigens associated with endometriosis |
| WO2011001276A1 (en) * | 2009-06-30 | 2011-01-06 | Philogen S.P.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
| EP2947096B1 (en) | 2009-08-05 | 2018-11-28 | Philogen S.p.A. | Targeting of bone marrow neovasculature |
| WO2011107586A1 (en) * | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
| RU2584597C2 (ru) | 2010-08-13 | 2016-05-20 | Рош Гликарт Аг | Антитела против а2 тенасцина с и способы их применения |
| ES2657743T3 (es) | 2011-07-19 | 2018-03-06 | Philogen S.P.A. | Terapia secuencial con anti-CTLA-4 e IL-2 dirigida |
| EP3834847A1 (en) | 2011-07-27 | 2021-06-16 | Philogen S.p.A. | Il-12 immunoconjugate |
| JP6241912B2 (ja) * | 2012-04-27 | 2017-12-06 | 国立研究開発法人量子科学技術研究開発機構 | 核医学診断装置の制御方法、核医学診断装置、および診断剤キット |
| CN104768563B (zh) | 2012-10-03 | 2020-02-28 | 菲罗根股份公司 | 与炎性肠病有关的抗原 |
| PL2766048T3 (pl) | 2012-10-12 | 2015-05-29 | Medimmune Ltd | Pirolobenzodiazepiny i ich koniugaty |
| US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP3102242A2 (en) * | 2014-02-03 | 2016-12-14 | Philochem AG | Targeted drug conjugates |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10647760B2 (en) | 2015-12-11 | 2020-05-12 | Philogen S.P.A. | Antibodies for treatment and diagnosis of inflammatory bowel disease |
| ES2864095T3 (es) | 2016-04-15 | 2021-10-13 | Philogen Spa | Anticuerpo anti-tenascina no glicosilado |
| EP3455252B1 (en) | 2016-05-11 | 2022-02-23 | F. Hoffmann-La Roche AG | Modified anti-tenascin antibodies and methods of use |
| JP7285076B2 (ja) | 2016-05-11 | 2023-06-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子 |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| JP6925431B2 (ja) | 2016-11-09 | 2021-08-25 | フィロジェン エッセ．ピー．アー． | Ｉｌ２及びｔｎｆ突然変異体のイムノコンジュゲート |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| EP3601346A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| EP3634999A1 (en) | 2017-06-07 | 2020-04-15 | Philogen S.p.A. | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| CN113286616A (zh) | 2018-05-23 | 2021-08-20 | Adc治疗有限公司 | 分子佐剂 |
| US20210277118A1 (en) * | 2018-06-21 | 2021-09-09 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| US20220119450A1 (en) | 2019-02-04 | 2022-04-21 | University Of Tartu | Bi-specific extracellular matrix binding peptides and methods of use thereof |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| WO2022073038A1 (en) | 2020-10-02 | 2022-04-07 | Abbvie Inc. | Interleukin-22 (il-22) fusion proteins and uses thereof |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| IT1307864B1 (it) * | 1999-04-20 | 2001-11-19 | Istituto Naz Per La Ricerca Su | Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di |
| EP1259548A1 (en) * | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2005
- 2005-10-31 JP JP2007539520A patent/JP2008518609A/ja not_active Ceased
- 2005-10-31 CA CA002586661A patent/CA2586661A1/en not_active Abandoned
- 2005-10-31 EP EP05813654A patent/EP1817345B9/en not_active Not-in-force
- 2005-10-31 CN CN200580044755.0A patent/CN101090913B/zh not_active Expired - Fee Related
- 2005-10-31 AU AU2005304031A patent/AU2005304031B2/en not_active Ceased
- 2005-10-31 MX MX2007005582A patent/MX2007005582A/es active IP Right Grant
- 2005-10-31 EA EA200700991A patent/EA013537B1/ru not_active IP Right Cessation
- 2005-10-31 AT AT05813654T patent/ATE432293T1/de active
- 2005-10-31 ES ES05813654T patent/ES2327349T3/es active Active
- 2005-10-31 BR BRPI0517967A patent/BRPI0517967B8/pt not_active IP Right Cessation
- 2005-10-31 PT PT05813654T patent/PT1817345E/pt unknown
- 2005-10-31 DE DE602005014665T patent/DE602005014665D1/de active Active
- 2005-10-31 KR KR1020077012900A patent/KR20070085892A/ko not_active Application Discontinuation
- 2005-10-31 US US11/718,919 patent/US7968685B2/en not_active Expired - Fee Related
- 2005-10-31 PL PL05813654T patent/PL1817345T3/pl unknown
- 2005-10-31 WO PCT/EP2005/011624 patent/WO2006050834A2/en active Application Filing
- 2005-10-31 DK DK05813654T patent/DK1817345T3/da active
- 2005-10-31 SI SI200530750T patent/SI1817345T1/sl unknown
- 2005-10-31 EP EP09006700A patent/EP2157102A1/en not_active Withdrawn
-
2008
- 2008-05-26 HK HK08105811.8A patent/HK1115756A1/zh not_active IP Right Cessation
-
2009
- 2009-08-03 CY CY20091100814T patent/CY1110481T1/el unknown
-
2012
- 2012-04-17 JP JP2012093587A patent/JP5127085B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005304031B2 (en) | 2009-04-23 |
| DE602005014665D1 (de) | 2009-07-09 |
| JP2008518609A (ja) | 2008-06-05 |
| PL1817345T3 (pl) | 2009-10-30 |
| PT1817345E (pt) | 2009-08-21 |
| EP2157102A1 (en) | 2010-02-24 |
| JP2012176957A (ja) | 2012-09-13 |
| BRPI0517967B1 (pt) | 2020-09-15 |
| CN101090913A (zh) | 2007-12-19 |
| EA200700991A1 (ru) | 2007-12-28 |
| EP1817345A2 (en) | 2007-08-15 |
| JP5127085B2 (ja) | 2013-01-23 |
| BRPI0517967A (pt) | 2008-10-28 |
| KR20070085892A (ko) | 2007-08-27 |
| HK1115756A1 (zh) | 2008-12-05 |
| CN101090913B (zh) | 2015-11-25 |
| US7968685B2 (en) | 2011-06-28 |
| BRPI0517967B8 (pt) | 2021-05-25 |
| EP1817345B9 (en) | 2009-11-18 |
| ATE432293T1 (de) | 2009-06-15 |
| CA2586661A1 (en) | 2006-05-18 |
| ES2327349T3 (es) | 2009-10-28 |
| US20080056997A1 (en) | 2008-03-06 |
| EP1817345B1 (en) | 2009-05-27 |
| EA013537B1 (ru) | 2010-06-30 |
| WO2006050834A2 (en) | 2006-05-18 |
| SI1817345T1 (sl) | 2009-10-31 |
| MX2007005582A (es) | 2007-09-11 |
| CY1110481T1 (el) | 2015-04-29 |
| AU2005304031A1 (en) | 2006-05-18 |
| WO2006050834A3 (en) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1817345T3 (da) | Antistoffer mod tenascin-C | |
| NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
| CY1119102T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων | |
| ATE478094T1 (de) | Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate,die diese enthalten | |
| CY1116256T1 (el) | Il-17 ανταγωνιστικα αντισωματα | |
| EA200801172A1 (ru) | Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения | |
| RS53168B (en) | Antibodies and Immunoconjugates and Their Use | |
| ATE530195T1 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| DK3085783T3 (da) | Bispecifikt antistof som substitution for funktionelle proteiner | |
| ATE505544T1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
| GEP20115226B (en) | P-cadherin antibodies | |
| BRPI0506771A (pt) | anticorpo, e, composição farmacêutica | |
| EA200800952A1 (ru) | Конъюгаты антитело-лекарство и способы применения | |
| DK1766093T3 (da) | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf | |
| BRPI0918555A2 (pt) | anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição. | |
| WO2006076594A3 (en) | Antibodies and fc fusion proteins with altered immunogenicity | |
| ATE525397T1 (de) | Antikörpermoleküle mit spezifität für humanes il- 1 beta | |
| AR058325A1 (es) | Anticuerpos anti mn y metodos para su utilizacion | |
| RS53708B1 (en) | ANTIBODY MOLECULES SPECIFIC TO HUMAN IL-6 | |
| ATE528319T1 (de) | Krebsbehandlung mit anti-il-1-antikörpern | |
| EP2192132A3 (en) | Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation | |
| ATE458819T1 (de) | Konjugat mit p21-protein zur krebsbehandlung | |
| ATE478894T1 (de) | Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept |